Application of picamod in preparation of medicine for treating diabetic retinopathy

A technology for diabetic retina and diabetes, which is applied in the application field of small molecule heparanase inhibitors, in the preparation of drugs for the treatment of diabetic retinopathy, and achieves the effect of avoiding intraocular complications

Inactive Publication Date: 2020-10-09
SUZHOU MUNICIPAL HOSPITAL
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] The purpose of the present invention is to provide a new therapeutic drug for diabetic reti

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of picamod in preparation of medicine for treating diabetic retinopathy
  • Application of picamod in preparation of medicine for treating diabetic retinopathy
  • Application of picamod in preparation of medicine for treating diabetic retinopathy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0027] 1. Experimental method:

[0028] (1) Establishment of mouse DM model

[0029] A 6-week-old C57BL / 6J mouse was selected and given 5 intraperitoneal injections of streptozotocin (STZ; 60 mg / kg / day), and another mouse of the same age was injected with citric acid as a control. Five days after the injection, blood was collected from the tail vein of the mice for a week, and blood glucose levels were measured with a blood glucose meter. The blood glucose concentration of the mice remained above 250 mg / dl (13.89 mmol / L) for 3 consecutive days, which proved that the modeling was successful. From the first injection, the mice were sacrificed and samples were taken 12 weeks later.

[0030] (2) Drug intervention in mice

[0031]Both PBS and PG545 were injected intraperitoneally, once a week, and given to mice in the 12 weeks of the experiment. Mice were randomly divided into six groups: normal control group (citric acid injection), diabetes (diabetic; STZ injection) group, so...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the field of ophthalmic treatment medicines, in particular to an application of picamod in preparation of a medicine for treating diabetic retinopathy. The application has theadvantages that the application of the PG545 in preparing the medicine for treating the diabetic retinopathy is provided, and the problem that no effective method for treating the diabetic retinopathy exists at present is solved. The PG545 is intraperitoneal injection, so that intraocular complications, such as intraocular hypertension and intraocular inflammation, possibly caused by repeated intravitreous injection are avoided. The PG545 alleviates the weight gain and fasting blood glucose level of diabetic mice. The retinal edema and inflammatory cell infiltration caused by diabetes mellitus are relieved through intraperitoneal injection of the PG545. Intraperitoneal injection of the PG545 reduces proinflammatory factors IL-1 beta and TNF-alpha mRNA and protein levels in retinal tissuesof diabetic mice. In addition, the PG545 reduces the permeability of human retinal endothelial cells under a high glucose condition.

Description

technical field [0001] The invention relates to the technical field of ophthalmic treatment, in particular to the application of a small molecule heparanase inhibitor, picamimod, in the preparation of drugs for treating diabetic retinopathy. Background technique [0002] Diabetes mellitus (DM) is a metabolic disease, and diabetic retinopathy (DR) is one of the common chronic complications of DM and one of the leading causes of blindness in the working-age population. DR seriously affects the quality of life of DM patients and brings heavy economic burden to society and family. The prevalence of DR among diabetic population in mainland my country is 17.8%-29.2%, of which non-proliferative diabetic retinopathy (NPDR) is 13.6%-26.3%, and proliferative diabetic retinopathy (PDR) is 1.9% to 4.2%. NPDR is an early manifestation of DR, during which pericytes involved in maintaining the blood retinal barrier (BRB) undergo apoptosis, endothelial cells are damaged, and a cascade of m...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/704A61P3/10A61P9/10A61P27/02
CPCA61K31/704A61P3/10A61P9/10A61P27/02
Inventor 王莹
Owner SUZHOU MUNICIPAL HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap